Literature DB >> 20538861

Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Marie Pancera1, Jason S McLellan, Xueling Wu, Jiang Zhu, Anita Changela, Stephen D Schmidt, Yongping Yang, Tongqing Zhou, Sanjay Phogat, John R Mascola, Peter D Kwong.   

Abstract

HIV-1 resists neutralization by most antibodies. Two somatically related human antibodies, PG9 and PG16, however, each neutralize 70 to 80% of circulating HIV-1 isolates. Here we present the structure of the antigen-binding fragment of PG16 in monoclinic and orthorhombic lattices at 2.4 and 4.0 A, respectively, and use a combination of structural analysis, paratope dissection, and neutralization assessment to determine the functional relevance of three unusual PG9/PG16 features: N-linked glycosylation, extensive affinity maturation, and a heavy chain-third complementarity-determining region (CDR H3) that is one of the longest observed in human antibodies. Glycosylation extended off the side of the light chain variable domain and was not required for neutralization. The CDR H3 formed an axe-shaped subdomain, which comprised 42% of the CDR surface, with the axe head looming approximately 20 A above the other combining loops. Comprehensive sets of chimeric swaps between PG9 and PG16 of light chain, heavy chain, and CDR H3 were employed to decipher structure-function relationships. Chimeric swaps generally complemented functionally, with differences in PG9/PG16 neutralization related primarily to residue differences in CDR H3. Meanwhile, chimeric reversions to genomic V genes showed isolate-dependent effects, with affinity maturation playing a significant role in augmenting neutralization breadth (P = 0.036) and potency (P < 0.0001). The structural and functional details of extraordinary CDR H3 and extensive affinity maturation provide insights into the neutralization mechanism of and the elicitation pathway for broadly neutralizing antibodies like PG9 and PG16.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538861      PMCID: PMC2916520          DOI: 10.1128/JVI.00966-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density.

Authors:  D E McRee
Journal:  J Struct Biol       Date:  1999 Apr-May       Impact factor: 2.867

Review 2.  Evolutionary and immunological implications of contemporary HIV-1 variation.

Authors:  B Korber; B Gaschen; K Yusim; R Thakallapally; C Kesmir; V Detours
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

3.  Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen.

Authors:  Abigail V J Collis; Adam P Brouwer; Andrew C R Martin
Journal:  J Mol Biol       Date:  2003-01-10       Impact factor: 5.469

4.  Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.

Authors:  Hongyi Zhou; Yaoqi Zhou
Journal:  Protein Sci       Date:  2002-11       Impact factor: 6.725

5.  Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling.

Authors:  Donald Petrey; Zhexin Xiang; Christopher L Tang; Lei Xie; Marina Gimpelev; Therese Mitros; Cinque S Soto; Sharon Goldsmith-Fischman; Andrew Kernytsky; Avner Schlessinger; Ingrid Y Y Koh; Emil Alexov; Barry Honig
Journal:  Proteins       Date:  2003

6.  FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function.

Authors:  Richard D Taylor; Philip J Jewsbury; Jonathan W Essex
Journal:  J Comput Chem       Date:  2003-10       Impact factor: 3.376

Review 7.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

8.  Novel secondary Ig VH gene rearrangement and in-frame Ig heavy chain complementarity-determining region III insertion/deletion variants in de novo follicular lymphoma.

Authors:  C Kobrin; M Bendandi; L Kwak
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

9.  Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line.

Authors:  Philip J Reeves; Nico Callewaert; Roland Contreras; H Gobind Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

10.  Crystal structures of two human pyrophosphorylase isoforms in complexes with UDPGlc(Gal)NAc: role of the alternatively spliced insert in the enzyme oligomeric assembly and active site architecture.

Authors:  C Peneff; P Ferrari; V Charrier; Y Taburet; C Monnier; V Zamboni; J Winter; M Harnois; F Fassy; Y Bourne
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

View more
  149 in total

Review 1.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

2.  Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Authors:  Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

3.  Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Authors:  Mattia Bonsignori; David C Montefiori; Xueling Wu; Xi Chen; Kwan-Ki Hwang; Chun-Yen Tsao; Daniel M Kozink; Robert J Parks; Georgia D Tomaras; John A Crump; Saidi H Kapiga; Noel E Sam; Peter D Kwong; Thomas B Kepler; Hua-Xin Liao; John R Mascola; Barton F Haynes
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

4.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

5.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Ivelin Georgiev; Sijy O'Dell; Gwo-Yu Chuang; Ryan P Staupe; Jason S McLellan; Jason Gorman; Marie Pancera; Mattia Bonsignori; Barton F Haynes; Dennis R Burton; Wayne C Koff; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

6.  Pushing the envelope on HIV-1 neutralization.

Authors:  Joseph G Joyce; Jan ter Meulen
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

7.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

8.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

9.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.